Form 4: Altimmune Director David Drutz Reports Stock Transactions

David Drutz, a director at Altimmune, Inc., reported the acquisition and disposal of common stock and stock options on August 19, 2024, according to a Form 4 filing with the SEC.

Summary

• On August 19, 2024, David Drutz, a director of Altimmune, Inc., filed a Form 4 with the SEC detailing changes in beneficial ownership.
• Drutz acquired 20,000 shares of common stock at $2.60 and 21,750 shares at $2.50 through the exercise of stock options.
• He also disposed of 7,827 shares at $6.93 and 8,184 shares at $6.88 to cover the exercise price of the options.
• Following these transactions, Drutz directly owns 55,524 shares and indirectly owns 63,708 shares through Pacific Biopharma Associates, LLC.
• The filing also includes a Power of Attorney, granting Vipin K. Garg and Andrew Shutterly the authority to act on Drutz's behalf for SEC filings.

Sentiment

Score: 5

Explanation: The sentiment is neutral. The director exercised options and sold some shares to cover the cost, which is a common practice. It doesn't necessarily indicate a strong positive or negative outlook.

Positives

• The exercise of stock options by a director could be seen as a positive signal, indicating confidence in the company's future prospects.

Negatives

• The sale of shares to cover the exercise price could be interpreted as a need for liquidity or a lack of conviction in the company's short-term prospects.

Risks

• The transactions are subject to scrutiny by investors and regulators.
• Changes in beneficial ownership could impact investor sentiment.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the trading activities of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Comparison to Industry Standards

• Monitoring insider transactions is a standard practice in the financial industry.
• Similar filings are made by executives and directors at companies like Pfizer, Moderna, and Novavax, providing a benchmark for understanding insider activity in the biotechnology sector.
• The frequency and nature of these transactions can be compared to industry peers to assess the overall sentiment of company leadership.

Stakeholder Impact

• The transactions could influence investor perception of Altimmune's stock.
• Employees holding stock options may be affected by changes in the stock price.

Key Dates